Description: Virtual - Session 4A: Data Science-Driven MA Product Design Strategies

Description: Navigating Ambiguity with Stakeholders and Clients

Description: The Art of Storytelling with Mandy Geyer

Description: The Power of Stories to Change Minds

Description: "The purpose of this presentation is to give an overview of the CP2 requirements for Bermuda statutory reserves and capital, which went into effect for 2024 reporting, along with a summary of the impact of these new requirements. Some of the CP2 changes include bringing the Bermuda Solvency Capital Requirement (BSCR) more in line with other capital reporting regimes, such as Solvency II. For example, lapse, expense, interest rate, and equity shocks are now required to compute the lapse, expense, interest rate, and equity shock components of required capital. The Bermuda Monetary Authority (BMA) also clarified in the CP2 paper that borrowing under any form is not permitted in the Scenario Based Approach to computing the Best Estimate Liability (BEL), and realistic transaction costs must be reflected. Proving model safety controls are in place is another key component of the CP2 paper, and reinsurers/insurers must prove their model governance is up to standard. These new requirements pose operational challenges for insurers and reinsurers reporting under the Bermuda framework, and have an impact on the economic balance sheet. The presenters include folks working with AXIS software from Moody's, who have been involved in enhancing the software to align with Bermuda reporting standards, and consultants from Valani who worked with many companies on setting up their Bermuda reporting processes. All presenters are very knowledgeable on Bermuda reporting, and have observed the impact of the CP2 requirements. The presenters want to share their knowledge with fellow actuaries at this industry meeting, and hopefully inspire insightful discussions."

Description: Session 4B: Impact of GLP-1 Drugs on Health Care Cost Trend and Clinical Outcomes

Description: Session 10D: Medicare Advantage - Limit it or Use it to Replace Medicare + MedSupp?

Description: Session 6B: Unraveling the Mysteries of Cell & Gene Therapy Eligibility and Demand

Description: Session 9A: Medicaid Continuous Coverage Unwinding - A Risk Mitigation Case Study

Description: Session 5C: The Large Group Market - Navigating Its Evolution: Past, Present, and Future